US Pharma MarketingThe post EAN 2026: Sanofi’s Cenrifki post hoc data suggests lesions may not indicate failure appeared first on Clinical Trials Arena.
EAN 2026: Sanofi’s Cenrifki post hoc data suggests lesions may not indicate failure
While lesions have previously been associated with treatment failure of Cenrifki, Sanofi's post hoc analysis suggests this may not be the case. While lesions have previously been associated with treatment failure, Sanofi's post hoc analysis suggests this may not be the case. Sanofi presented the data at the 12th Congress of the European Academy of Neurology (EAN) 2026. Credit: Grand Warszawski / Shutterstock.com Post hoc analysis shows that local inflammatory lesions associated with treatment with Sanofi’s Cenrifki (tolebrutinib) in patients with multiple sclerosis (MS) may not be a sign of failure. In the pivotal Phase III HERCULES trial (NCT04411641) and…
While lesions have previously been associated with treatment failure of Cenrifki, Sanofi's post hoc analysis suggests this may not be the case.
Source: Clinical Trials Arena